Drug Class Review: Alzheimer's Drugs: Final Report [Internet]

Article Details

Citation
Copy to clipboard

Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T

Drug Class Review: Alzheimer's Drugs: Final Report [Internet]

.

PubMed ID
20480924 [ View in PubMed
]
Abstract

Alzheimer's disease (AD), the most common adult form of dementia. Currently available pharmacologic therapies, including cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, are considered symptomatic treatments based on their ability to slow the clinical progression of symptoms across cognitive, behavioral, and functional domains. The purpose of this review is to help policy makers and clinicians make informed choices about the use of ChEIs and memantine in the treatment of AD. We compare the efficacy, effectiveness, and safety of donepezil, galantamine, rivastigmine, tacrine, and memantine in patients with mild to severe AD.

DrugBank Data that Cites this Article

Drugs